Summary
The number of protein‐based pharmaceuticals reaching the marketplace has exponentially increased over the past few years. As the global demand for innovative protein therapeutics is growing each year, a large number of investors are pouring money in the market. Moreover, new developments in manufacturing & production technology have led to significant advancements in protein manufacturing and production. The global protein therapeutics market registered a robust growth rate of over 14% in 2008.
According to our new research report "Global Protein Therapeutics Market Analysis", the global protein therapeutics market is expected to grow at a CAGR of around 12% during 2010-2012. At present, the market is characterized by high cost treatments therapy and healthcare insurance which in turn helping the companies to generate more revenue.
Our report has found that the market is presently dominated by Monoclonal Antibodies. With double-digit growth projected for future, the segment is expected to bolster its dominant position. Insulin, Interferon Beta, G-CSF and coagulation factors are also exhibiting healthy growth rates. One of the biggest opportunity areas in the protein therapeutics market is biogenerics which are expected to create a multi-billion dollar market in future. Moreover, pharmaceutical contract research and manufacturing market is expected to grow at an unmatched rate on account of high cost factor in the market.
This report provides extensive information and rational analysis of the global protein therapeutics market. It includes detailed study of factors fueling growth in the protein therapeutics market to help clients gain deeper insight of the current and future trends in the global protein therapeutics market. The report also provides segment-wise market trends prevailing at regional level to provide an overview of developments taking place in these segments across the world.
Table of Contents
1. Analyst View
2. Global Proteins Therapeutic Market
2.1 Market Analysis
2.1.1 Market Size
2.1.2 Proteins Therapeutic Market vs Pharmaceutical Market
2.1.3 Market Segmentation
2.2 Future Outlook (2010-2012)
3. Industry Performance
3.1 Monoclonal Antibodies (mAb)
3.1.1 Market Size
3.1.2 By Application
3.1.3 Key Geographical Markets
3.1.4 Key Players and Drugs
3.1.5 Industry Analysis
3.1.6 Future Outlook (2010-2012)
3.2 Erythropoietin (EPO)
3.2.1 Market Size
3.2.2 By Application
3.2.3 Key Geographical Markets
3.2.4 Key Players and Drugs
3.2.5 Industry Analysis
3.2.6 Future Outlook (2010-2012)
3.3 Insulin
3.3.1 Market Size
3.3.2 By Application
3.3.3 Key Geographical Markets
3.3.4 Key Players and Drugs
3.3.5 Industry Analysis
3.3.6 Future Outlook (2010-2012)
3.4 Interferon (IFN)
3.4.1 Market Size
3.4.2 Key Geographical Markets
3.4.3 Key Players and Drugs
3.4.4 Industry Analysis
3.4.5 Future Outlook (2010-2012)
3.5 Human Growth Hormone (HGH)
3.5.1 Market Size
3.5.2 By Application
3.5.3 Key Geographical Markets
3.5.4 Key Players and Drugs
3.5.5 Industry Analysis
3.5.6 Future Outlook (2010-2012)
3.6 Blood Clotting Factor
3.6.1 Market Size
3.6.2 Key Players and Drugs
3.6.3 Industry Analysis
3.6.4 Future Outlook (2010-2012)
3.7 Follicle Stimulating Hormone (FSH)
3.7.1 Market Size
3.7.2 Key Players and Drugs
3.7.3 Industry Analysis
3.7.4 Future Outlook (2010-2012)
3.8 Granulocyte Colony Stimulating Factor (G-CSF)
3.8.1 Market Size
3.8.2 Key Players and Drugs
3.8.3 Industry Analysis
3.8.4 Future Outlook (2010-2012)
4. Emerging Market Trends
4.1 Biogenerics
4.2 Contract Research Outsourcing
4.3 Contract Manufacturing
4.4 Nanotechnology-enabled Drug Delivery Market
4.5 Healthcare Insurance
4.6 High Approval Rate
5. Growth Inhibitors
5.1 High R&D Cost
5.2 High Price
5.3 High Failure Rates in Phase-3 Clinical Trials
5.4 Insurance Reimbursements
5.5 Lack of Predictability in the Operating Environment
6. Key Players
6.1 Johnson & Johnson
6.2 Biogen Idec Inc.
6.3 Eli Lilly & Company
6.4 Novo Nordisk A/S
6.5 Sanofi-Aventis
6.6 Roche Group
6.7 Amgen Inc.
6.8 Genentech, Inc.
6.9 Merck Serono S.A
List of Figures:
Figure 2-1: Global-Proteins Therapeutic Market (Billion US$), 2007-2009
Figure 2-2: Global-Comparison of Proteins Therapeutic Market to Pharmaceutical Market (Billion US$), 2007 & 2008
Figure 2-3: Global-Proteins Therapeutic Market by Segment (%), 2008
Figure 2-4: Global-Forecast for Proteins Therapeutic Market (Billion US$), 2010-2012
Figure 2-5: Global-Forecast for Proteins Therapeutic Market by Segment (%), 2012
Figure 3-1: Global-Monoclonal Antibodies Market (Billion US$), 2007-2009
Figure 3-2: Global-Monoclonal Antibodies Market in Cancer Treatment (Billion US$), 2007-2009
Figure 3-3: Global-Monoclonal Antibodies Market in Rheumatoid Arthritis Treatment (Billion US$), 2007-2009
Figure 3-4: Global-Monoclonal Antibodies Market in Cardiovascular and Infectious Diseases Treatment (Billion US$), 2008
Figure 3-5: Global-Monoclonal Antibodies Market in Cardiovascular and Infectious Diseases Treatment (Billion US$), 2009
Figure 3-6: US-Monoclonal Antibodies Market (Billion US$), 2007-2009
Figure 3-7: US-Forecast for Monoclonal Antibodies Market (Billion US$), 2010-2012
Figure 3-8: Europe-Monoclonal Antibodies Market (Billion US$), 2007-2009
Figure 3-9: Europe-Forecast for Monoclonal Antibodies Market (Billion US$), 2010-2012
Figure 3-10: Europe-Forecast for Monoclonal Antibodies Market by Application (%), 2011
Figure 3-11: Japan-Monoclonal Antibodies Market (Billion JPY), 2007-2009
Figure 3-12: Japan-Forecast for Monoclonal Antibodies Market (Billion JPY), 2010-2012
Figure 3-13: Global-Share of Key Players in Monoclonal Antibodies Market (2008)
Figure 3-14: Global-Top Selling Monoclonal Antibodies (Billion US$)
Figure 3-15: Global-Forecast for Monoclonal Antibodies Market (Billion US$), 2010-2012
Figure 3-16: Global-Erythropoietin Market (Billion US$), 2006-2009
Figure 3-17: Global-First Generation Erythropoietin Market (Billion US$), 2006-2009
Figure 3-18: Global-First Generation Erythropoietin Alpha Market (Million US$), 2006-2009
Figure 3-19: Global-First Generation Erythropoietin Beta Market (Million US$), 2006-2009
Figure 3-20: Global-Second Generation Erythropoietin Market (Billion US$), 2006-2009
Figure 3-21: Global-Number of Patients on Dialysis (Million), 2007-2009
Figure 3-22: Global-Breakup of Patients on Dialysis by Region (%), 2008
Figure 3-23: Global-Number of New Cancer Cases (Million), 2008 & 2030
Figure 3-24: Global-Breakup of New Cancer Cases by Region (%), 2008
Figure 3-25: Europe-Erythropoietin & Untapped Erythropoietin Market for Chemotherapy (Million Euro), 2004
Figure 3-26: US-Share in Global Erythropoietin Market (%), 2008
Figure 3-27: Europe-Erythropoietin Market (Billion US$), 2007-2009
Figure 3-28: Europe-Forecast for Erythropoietin Market (Billion US$), 2010-2012
Figure 3-29: Europe-Erythropoietin Market in Renal Anemia Treatment (Million US$), 2007-2009
Figure 3-30: Europe-Erythropoietin Market in Oncology Treatment (Million US$), 2007-2009
Figure 3-31: Europe-First Generation Erythropoietin Patent Expiry by Major Country
Figure 3-32: Japan-Erythropoietin Market (Billion JPY), 2007-2009
Figure 3-33: Global-Forecast for Erythropoietin Market (Billion US$), 2010-2012
Figure 3-34: Europe-Forecast for Share of Oncology and Renal Anemia in Erythropoietin Market (%), 2016
Figure 3-35: Global-Insulin Market (Billion US$), 2006-2009
Figure 3-36: India-Number of Diabetic Patients (Million), 2008 & 2030
Figure 3-37: India-Insulin Market (Million US$), 2007-2009
Figure 3-38: India-Share of Key Players in Insulin Market
Figure 3-39: China-Insulin Market (Billion RMB), 2006-2009E
Figure 3-40: China-Share of Key Players in Insulin Market (Q3 2008)
Figure 3-41: US-Insulin Market (Billion US$), 2002-2006
Figure 3-42: US-Share of Key Players in Insulin Market (2008)
Figure 3-43: Russia-Insulin Market (Million US$), 2007-2009
Figure 3-44: Russia-Share of Key Players in Insulin Market (H1 2006)
Figure 3-45: Russia-Insulin Market by Channel of Sales (%), 2007
Figure 3-46: Japan-Insulin Market (Billion JPY), 2007-2009
Figure 3-47: Japan-Share of Key Players in Insulin Market (2008)
Figure 3-48: Germany-Share of Insulin in Genetically Manufactured Pharmaceuticals Market (2007)
Figure 3-49: Brazil-Insulin Market (Million BRL), 2007-2009
Figure 3-50: Brazil-Share of Key Players in Insulin Market (2007)
Figure 3-51: Global-Share of Key Players in Insulin Market (2008)
Figure 3-52: Share of Novo Nordisk in the Insulin Market of US, Europe and Japan (2008)
Figure 3-53: Global-Share of Brands in Insulin Market (2008)
Figure 3-54: Global-Number of Diabetic Patients (Million), 2007 & 2025
Figure 3-55: Global-Forecast for Insulin Market (Billion US$), 2010-2012
Figure 3-56: Global-Interferon Market (Billion US$), 2007-2009
Figure 3-57: Global-Share of Alpha and Beta in Interferon Market (2008)
Figure 3-58: Global-Interferon Alpha Market (Billion US$), 2007-2009
Figure 3-59: Global-Forecast for Hepatitis B Treatment Market (Billion US$), 2010-2015
Figure 3-60: Global-Hepatitis C Treatment Market (Billion US$), 2007-2009
Figure 3-61: Global-Forecast for Hepatitis C Treatment Market (Billion US$), 2010-2015
Figure 3-62: Global-Forecast for Share of Interferon in Hepatitis C Treatment Market (2015)
Figure 3-63: Global-Interferon Beta Market (Billion US$), 2007-2009
Figure 3-64: Global-Multiple Sclerosis Treatment Market (Billion US$), 2007-2009
Figure 3-65: US-Interferon Market (Billion US$)
Figure 3-66: Europe-Interferon Market (Million US$)
Figure 3-67: Japan-Interferon Market (Billion JPY), 2007-2009
Figure 3-68: Global-Forecast for Interferon Market (Billion US$), 2010-2012
Figure 3-69: Global-Human Growth Hormone Market (Billion US$), 2007-2009
Figure 3-70: US, Europe & Japan-Number of Patients with Pediatric Growth Hormone Deficiency ('000)
Figure 3-71: Global-Share of Growth Hormones in Treatment of Pediatric Short Stature (2006)
Figure 3-72: Global-Adult Growth Hormone Deficiency Market (Million US$), 2006
Figure 3-73: Global-Human Growth Hormone Market by Region (%), 2007
Figure 3-74: US-Human Growth Hormone Market (Billion US$), 2007-2009
Figure 3-75: Japan & Europe-Human Growth Hormone Market (Million US$), 2007
Figure 3-76: Global-Share of Key Players in Human Growth Hormone Market (2008)
Figure 3-77: Global-Forecast for Human Growth Hormone Market (Billion US$), 2010-2012
Figure 3-78: Global-Blood Clotting Factor Market (Billion US$), 2007-2009
Figure 3-79: Global-Share of Blood Clotting Factor Market by Segment (2008)
Figure 3-80: Global-Share of Key Players in Blood Clotting Factor Market (2008)
Figure 3-81: Global-Forecast for Blood Clotting Factor Market (Billion US$), 2010-2012
Figure 3-82: Global-Follicle Stimulating Hormone Market (Billion US$), 2007-2009
Figure 3-83: Global-Forecast for Follicle Stimulating Hormone Market (Billion US$), 2010-2012
Figure 3-84: Global-Granulocyte Colony Stimulating Factor Market (Billion US$), 2007-2009
Figure 3-85: US-Share in Global Granulocyte Colony Stimulating Factor Market
Figure 3-86: Global-Forecast for Granulocyte Colony Stimulating Factor Market (Billion US$), 2010-2012
Figure 4-1: Global-Sales of Biologics by Year of Patent Expiration (Billion US$), 2008-2015
Figure 4-2: Global-Biogenerics Market (Billion US$), 2007 & 2011
Figure 4-3: Global-Contract Research Outsourcing Market (Billion US$), 2008 & 2013
Figure 4-4: Global-Market for Pharmaceutical Contract Manufacturing (Billion US$), 2008-2012
Figure 4-5: Global-Nanotechnology-enabled Drug Delivery Market (Billion US$), 2007 & 2012
Figure 4-6: Global-Health Insurance Market (Billion US$), 2008-2012
Figure 4-7: Global-Approval Rate for Biopharmaceuticals and Conventional Pharmaceuticals
Figure 5-1: Global-Comparison of Annual Cost of Biotech Drugs to Traditional Drugs (US$), 2006
Figure 5-2: Global-Failure Rate in Phase-3 Clinical Trials of Biotech and Traditional Drugs
List of Tables:
Table 3-1: Global-Key Players and Drugs in Erythropoietin Alpha Market (Billion US$), 2008
Table 3-2: Global-Key Players and Drugs in Erythropoietin Beta Market (Billion US$), 2008
Table 3-3: Global-Key Players and Drugs in Darbepoetin Alpha Market (Billion US$), 2008
Table 3-4: China-Diabetic Patients in Age Group 20-79 Years ('000), 2007
Table 3-5: China-Forecast for Diabetic Patients in Age Group 20-79 Years ('000), 2025
Table 3-6: US-Diabetic Patients in Age Group 20-79 Years ('000), 2007
Table 3-7: US-Forecast for Diabetic Patients in Age Group 20-79 Years ('000), 2025
Table 3-8: Russia-Diabetic Patients in Age Group 20-79 Years ('000), 2007
Table 3-9: Russia-Forecast for Diabetic Patients in Age Group 20-79 Years ('000), 2025
Table 3-10: Japan-Diabetic Patients in Age Group 20-79 Years ('000), 2007
Table 3-11: Japan-Forecast for Diabetic Patients in Age Group 20-79 Years ('000), 2025
Table 3-12: Germany-Diabetic Patients in Age Group 20-79 Years ('000), 2007
Table 3-13: Germany-Forecast for Diabetic Patients in Age Group 20-79 Years ('000), 2025
Table 3-14: Brazil-Diabetic Patients in Age Group 20-79 Years ('000), 2007
Table 3-15: Brazil-Forecast for Diabetic Patients in Age Group 20-79 Years ('000), 2025
Table 3-16: Global-Key Players and Drugs in Interferon Alpha Market (Billion US$), 2008
Table 3-17: Global-Key Players and Drugs in Interferon Beta Market (Billion US$), 2008
Table 3-18: Global-Key Players and Drugs in Human Growth Hormone Market (Million US$), 2008
Table 3-19: Global-Key Players and Drugs in Blood Clotting Factor Market (Million US$), 2008
Table 3-20: Global-Key Players and Drugs in Follicle Stimulating Hormone Market (Million US$), 2008
Table 3-21: Global-Key Players and Drugs in Granulocyte Colony Stimulating Factor Market (Million US$), 2008
Table 4-1: US & Europe-Patent Expiry Dates for Recombinant Biologics
Table 4-2: US & EU-Forecast for Biogenerics Market by Segment (Million US$), 2010
